SCHEDULE: Fairmount Funds Trims Spyre Stake in $400M Block Trade

Fairmount Funds Management reduced its position in Spyre Therapeutics through a significant block trade following the conversion of preferred shares and a board resignation.

Summary

• Fairmount Healthcare Fund II converted 16,667 shares of Series B Non-Voting Convertible Preferred Stock into 666,680 shares of Common Stock on June 23, 2026.
• On the same day, the fund executed a massive block trade, selling 4,684,781 shares of Common Stock at a price of $85.31 per share.
• The total proceeds from the block trade sale amount to approximately $399.66 million.
• Peter Harwin resigned from the Board of Directors effective May 27, 2026, though he remains a managing member of the reporting funds.
• The reporting group's beneficial ownership is currently capped at 9.99% of the outstanding Common Stock due to specific conversion and ownership limitations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive to neutral; while a major sale occurred, the high execution price and the fact that the fund maintained its maximum allowable 9.99% stake suggest continued confidence at a higher valuation floor.

Positives

• The block trade was executed at a high valuation of $85.31 per share, indicating strong institutional demand for the stock.
• The conversion of Series B Preferred Stock into Common Stock simplifies the company's capital structure.
• The reporting persons still maintain a maximum allowable stake of 9.99%, showing continued significant investment in the company.

Negatives

• A major institutional investor and board-represented fund sold a significant portion of its holdings (over 4.6 million shares).
• The resignation of Peter Harwin from the Board of Directors removes a key investment professional from the company's direct governance.

Risks

• Large-scale selling by major shareholders can create downward pressure on the stock price or signal a peak in valuation to other investors.
• The loss of a board member associated with a lead investor may change the dynamic of board oversight.
• The reporting group holds a significant amount of Series A Preferred Stock that remains unconverted due to the 9.99% ownership cap, which could lead to future dilution or further large sales if the cap is managed.

Future Outlook

The reporting persons intend to review their investment on a continuing basis and may engage in discussions with management or the board, or change their position depending on market conditions and the company's performance.

Management Comments

• Mr. Harwin's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Industry Context

StockSavvy.ai notes that large block trades by specialized biotech venture firms like Fairmount often occur after significant share price appreciation, allowing the fund to return capital to limited partners while maintaining a core 'capped' position in the company.

Comparison to Industry Standards

• The $85.31 share price represents a robust valuation compared to many clinical-stage peers in the immunology and inflammation space.
• The use of a 9.99% beneficial ownership cap is a standard industry practice to avoid triggering Section 16 'short-swing' profit rules.

Management Changes

Corporate Governance

Related Party Transactions

• The conversion of Series B Preferred Stock and the subsequent block trade involve Fairmount Healthcare Fund II, which is a significant shareholder and was previously represented on the board.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the large volume of shares moved in the block trade.
• The company's capital structure is slightly simplified through the conversion of preferred shares.

Next Steps

• Monitor for any further Form 4 filings or 13D amendments if the group sells more shares to stay under the 9.99% cap.
• Watch for the appointment of a new director to fill the vacancy left by Peter Harwin.

Key Dates

Recommendation

The stock has reached a valuation where a lead investor is taking significant profits, yet they are maintaining the maximum possible stake allowed without triggering regulatory hurdles. This suggests the company is fairly valued but still holds long-term interest for its primary backers.

Keywords

Spyre Therapeutics, Fairmount Funds Management, Block Trade, Insider Selling, Series B Preferred Conversion, Peter Harwin, Biotechnology, Schedule 13D